Skip to content

Psoriatic Arthritis Health Center

Otezla Approved for Psoriatic Arthritis

Condition affects some with psoriasis
Font Size
A
A
A

WebMD News from HealthDay

By Scott Roberts

HealthDay Reporter

FRIDAY, March 21, 2014 (HealthDay News) -- Otezla (apremilast) has been approved by the U.S. Food and Drug Administration to treat adults with active psoriatic arthritis, a condition associated with the autoimmune skin disease psoriasis.

Most people develop psoriasis first and are subsequently diagnosed with psoriatic arthritis. Common symptoms of the latter are joint pain, stiffness and swelling.

Otezla was evaluated in clinical studies involving nearly 1,500 people with active psoriatic arthritis. In a Friday news release, the FDA said Otezla users should be monitored carefully for unexplained weight loss or signs of depression. Pregnant women must register for the drug's use, the agency added.

The most common side effects noted during clinical testing included diarrhea, nausea and headache.

Otezla is produced for Celgene Corp., based in Summit, N.J.

Today on WebMD

5 Types Of Psoriatic Arthritis
Article
Psoriasis Overview
Slideshow
 
Pain Tips
Slideshow
young woman touching skin
Evaluator
 
Woman rubbing shoulder
Slideshow
Psoriasis Laser Therapy
Video
 
Psoriatic Arthritis Do You Know The Symptoms
Article
Woman scratching shoulder
Health Check